Wockhardt, one of India’s oldest drug firms, has refused to comment on media reports that it is aiming to demerge its formulations operation and then sell a significant minority stake in the business to reduce a mounting debt pile. The loss-making company said it would not respond to market “speculation.”
“We would like to state that being a responsible corporate, we do not comment on market rumour and/or speculation,” Wockhardt...




